



OxySure (OXYS) Announces Key New Staff Additions

New Positions Driven by Impressive Growth Plan and Focus on Medical Device Platform

Frisco, Texas, January 22, 2015 – OxySure Systems, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology today announced the naming of key new staff additions. These announcements are a direct result of the firm’s impressive growth plan for 2015 in addition to its focus on developing its medical device platform.

Specific details on the staff announcements are as follows:

* Jeffrey Schlueter – Territory Manager, Chicago: Mr. Schlueter joins OxySure after over 20 years as a sales professional with a number of medical device companies, such as Synvasive Technology, ConMed Corporation and Midway Medical Products. Mr. Schlueter has extensive experience selling both direct and through distribution.

At OxySure Mr. Schlueter will focus on developing and supporting new and existing distribution partnerships and strategic alliances, and developing and supporting sales from large corporate and industrial customers in Chicago and surrounding areas in the state of Illinois.

* Gloria Cornis – Territory Manager, Phoenix: Ms. Cornis joins OxySure after over 19 years as a Digital Solutions Specialist with Toshiba where she was a multiple President’s Club winner.

At OxySure Ms. Cornis will focus on developing and supporting new and existing distribution partnerships and strategic alliances, and developing and supporting sales from large corporate and industrial customers in Phoenix and surrounding areas in the state of Arizona. Ms. Cornis brings a strong B2B sales and marketing background to her new position.

* Kathryn Jayne – Director, Regulatory Affairs & Quality Assurance: Ms. Jayne joins OxySure with 19 years of experience in the medical device industry, with experience in both domestic and international regulations and quality systems.

At OxySure Ms. Jayne will develop, implement and manage all aspects of the Company’s regulatory affairs and quality assurance programs to ensure compliance with mandatory and voluntary regulations (both domestic and international). Ms. Jayne will establish and maintain a robust quality system to ensure the product and processes of OxySure meet and exceed customer and regulatory requirements.

* Richard Bryant – Manufacturing Manager: Mr. Bryant joins OxySure after over 20 years in FDA controlled, medical device manufacturing and production management environments.

At OxySure Mr. Bryant will focus on managing and improving production systems and processes, working with production staff and line leads, including production travelers, parts, the inventory system, quality system, and shipping & receiving system. Mr. Bryant will plan and manage production outputs, managing assigned resources, and effectively lead and supervise teams of production employees.

* Richard Marcus – Engineer, Innovation Solutions Group: Mr. Marcus joins OxySure with significant experience in engineering design and medical device development.

At OxySure Mr. Marcus will develop, design, test and evaluate improvements to existing products; develop new products and manufacturing processes; and evaluate products, technologies and intellectual property associated with acquisition targets.

“At OxySure, we are laser-focused on growing our business rapidly by providing quality, innovative and lifesaving products and services,” said Julian Ross, OxySure CEO. “To this end, we continue to bring on board the most talented individuals in their respective fields. I welcome our latest additions to the OxySure team and I am excited at the value they will bring to our Company, our industry, and, most importantly, our customers.”

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. www.OxySure.com

Forward-Looking Statements

Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management's control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Systems, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said

safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Systems, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Systems, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2013.

Investor Contacts:

Renmark Financial Communications, Inc.

Bettina Filippone: bfilippone@renmarkfinancial.com

John Boidman: jboidman@renmarkfinancial.com

Tel.: (416) 644-2020 or (514) 939-3989

www.renmarkfinancial.com/

Redchip Companies, Inc.

Jon Cunningham: jon@redchip.com

800-733-2447, ext. 107

www.redchip.com/